Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
British Journal of Cancer2012Vol. 107(9), pp. 1481–1487
Citations Over TimeTop 10% of 2012 papers
David A. Reardon, James E. Herndon, Katherine B. Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Eric Lipp, Sith Sathornsumetee, Jeremy N. Rich, John H. Sampson, Allan H. Friedman, Susan Boulton, Darell D. Bigner, Henry S. Friedman, James J. Vredenburgh
Abstract
The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial.
Related Papers
- → Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma(2016)27 cited
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- → Rekurrens glioblastomában szenvedő betegek kezelése bevacizumab-monoterápiával(2016)1 cited
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)